Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a pandemic disease spread in the whole world and is found among the population of different age groups. Nonalcoholic steatohepatitis (NASH) is a progressing condition of NAFLD often associated with fibrosis and can result in the development of cirrhosis or hepatocellular liver carcinoma. Hypercholesterolemia (HC) is one of the manifestations of NASH, and at the
same time HC is one of the risk factors promoting the development of cardiovascular and cerebrovascular failures. Objective of the study was to investigate the efficacy of a ccomprehensive hypolipidemic therapy including statin (Rosuvastatin) and hepatoprotector (Hepadif) in modeling HC with NASH in the experiment
conducted on animals. On the 60th day of the experiment in the III group of experimental animals receiving a comprehensive hypolipidemic therapy with administration of Rosuvastatin and hepatoprotector Hepadif resulted in the following: the level of the whole cholesterol 54% decreased, low density lipoproteins (LDL) 73% decreased, high density lipoproteins (HDL) 42% increased. Activity of the hepatic transaminase was
characterized by a marked tendency to decrease: ALT activity 57% decreased, AST activity – 71% as much (р<0,05), as compared to the control group. Pathomorphological examination of the liver tissue in the III group of experimental animals found less pronounced signs of steatohepatitis.
